Restoring Insulin Secretion Pediatric Medication Study
The RISE Pediatric Medication Study investigates the efficacy of metformin alone versus a combination of basal insulin glargine followed by metformin in restoring beta-cell function in children aged 10-19 with prediabetes and early type 2 diabetes. Given the rising prevalence of type 2 diabetes in pediatric populations, successful outcomes could position the sponsor favorably in a growing market. The study's completion and results may enhance the competitive landscape for diabetes treatments targeting pediatric patients, particularly against existing therapies like insulin and metformin. Stakeholders should consider potential partnerships or licensing opportunities based on the results, as well as the implications for reimbursement strategies in pediatric diabetes care.
Indication: Prediabetes
Modality: small molecule
Target: Beta-cell function recovery and insulin sensitivity improvement in pediatric patients with prediabetes and early type 2 diabetes.
Sponsor: RISE Study Group
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 17, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Beta-cell function recovery and insulin sensitivity improvement in pediatric patients with prediabetes and early type 2 diabetes.
View original source fields
Condition raw: Prediabetes, Type 2 Diabetes
Condition normalized: Prediabetes, Type 2 Diabetes
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Beta-cell function recovery and insulin sensitivity improvement in pediatric patients with prediabetes and early type 2 diabetes.
Target normalized: Beta-cell function recovery and insulin sensitivity improvement in pediatric patients with prediabetes and early type 2 diabetes.